Cardimax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardimax

What is Cardimax?

Cardimax is a pharmaceutical preparation containing levocarnitine, a naturally occurring derivative of the amino acid lysine. It is classified as a metabolic modifier and is used to address specific biochemical deficiencies within the body.

Therapeutic Role

Levocarnitine plays a fundamental role in energy metabolism. Its primary function is to facilitate the transport of long-chain fatty acids into the mitochondria, the energy-producing centers of the cells. Once inside the mitochondria, these fatty acids undergo a process called beta-oxidation to produce adenosine triphosphate (ATP), which serves as the main energy source for cellular functions.

Mechanism of Action

In addition to its role in fatty acid transport, Cardimax assists in the removal of short-chain and medium-chain fatty acids from the mitochondria. This process helps maintain the necessary levels of coenzyme A, which is vital for continuous energy production and the detoxification of metabolic by-products. By supporting these pathways, Cardimax helps stabilize metabolic processes in tissues that rely heavily on fatty acid oxidation, such as the heart and skeletal muscles.

What side effects are possible with Cardimax?

Possible Side Effects and Safety Information

The safety profile of Cardimax (Levocarnitine) is officially documented by regulatory authorities, detailing the types and classifications of adverse reactions observed during clinical use. The majority of reported effects involve the gastrointestinal system and are generally described as transient and manageable.


Key Adverse Reactions and Organ Systems

The most frequently documented adverse reactions are often mild, including nausea, vomiting, diarrhea, abdominal cramps, and stomach pain. The drug's regulatory profile also notes the potential for a characteristic body odor (often described as "fishy"). These types of effects are sometimes related to the rate of oral consumption, and regulatory documents suggest they may diminish with a slower intake.

Adverse reactions are classified into system-organ classes, with documented events affecting Gastrointestinal Disorders, Nervous System Disorders, and the Immune System.


Serious Safety Concerns and Specific Populations

Official labeling highlights the potential for Serious Hypersensitivity Reactions, such as anaphylaxis, which are clinically significant events, particularly with the intravenous route. There is also a specific safety note regarding the risk of seizures; patients with a pre-existing history of seizure activity may experience an increase in frequency or severity.

Specific safety constraints apply to certain populations. Chronic, high-dose oral use of Levocarnitine in patients with severe renal impairment is restricted due to the documented risk of accumulating potentially toxic metabolites (trimethylamine, TMAO). Furthermore, the regulatory profile includes reports of an increased International Normalised Ratio (INR) in patients concurrently receiving warfarin therapy, necessitating monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Cardimax (diltiazem) is a serious medical emergency primarily affecting the cardiovascular system and requires immediate, urgent medical attention. Do not wait for symptoms to worsen.

Documented Overdose Presentations

Overdose with this medication has been officially documented to cause significant cardiovascular compromise. Key clinical manifestations include:

  • Hypotension: Dangerously low blood pressure.
  • Bradycardia: A significantly slow heart rate.
  • Conduction Disturbances: Abnormalities in the heart's electrical rhythm, such as atrioventricular (AV) block.
  • Severe Dizziness or Fainting (Syncope): Resulting from reduced blood flow to the brain.

Overdose with sustained-release formulations presents a specific risk because the onset of maximum toxicity may be delayed for up to 12 to 16 hours after ingestion, even if initial symptoms are mild or absent. Co-ingestion with alcohol may also increase the rate of drug release, intensifying the risk.

Emergency Response

If an overdose is suspected or confirmed, call emergency medical services immediately. Treatment is supportive and is often initiated in a hospital setting to stabilize the heart rate and blood pressure. Necessary emergency measures may involve the use of intravenous fluids, vasopressors, and an antidote such as calcium gluconate to manage the critical effects on the heart.

Therapeutic Uses of Cardimax

What Cardimax Treats: Main Uses and Benefits

Cardimax (Levocarnitine) is used for managing symptoms related to metabolic imbalance caused by a documented carnitine deficiency. The medication may be part of symptomatic management across key domains where this metabolic issue causes noticeable physiological strain.

The medication is applied across domains where additional symptomatic support is needed, including in conditions such as primary systemic carnitine deficiency, secondary deficiency resulting from certain inborn errors of metabolism, and deficiency linked to end-stage renal disease in hemodialysis patients. It helps address symptom clusters related to physical discomfort, such as skeletal muscle weakness, chronic fatigue, and painful muscle cramps. It is also applied in clinical settings that involve acute or unstable symptom patterns, including specific cardiac manifestations which may be associated with the deficit.

“This treatment contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

Cardimax is considered relevant for easing symptoms linked to organ-specific functional stress, where it supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact: Focus on Chronic Fatigue and Muscle Strain The medication contributes to easing the overall symptom load and helps improve day-to-day comfort by supporting those with chronic muscle weakness and fatigue, particularly for adults undergoing long-term dialysis treatment or children managing metabolic conditions.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility information for Cardimax (Trimetazidine), as defined by authoritative government regulatory documents.


Mandatory Exclusions (Contraindications)

Category Regulatory Status
Movement Disorders Contraindicated for patients with Parkinson's disease, parkinsonian symptoms, tremors, restless legs syndrome, or other related movement disorders.
Renal Impairment Contraindicated for patients with severe renal impairment (creatinine clearance less than 30 ml/min).
Hypersensitivity Contraindicated for patients with a known allergy to the active substance or any of the medicine's excipients.

Populations with Restricted or Conditional Use

Category Regulatory Status
Moderate Renal Impairment Requires caution and a dose reduction (creatinine clearance 30-60 ml/min).
Elderly Patients Requires caution for those over 75 years old, due to potential age-related decrease in kidney function and increased risk of extrapyramidal symptoms.

Use Not Recommended

  • Pediatric Population: Use in children and adolescents (under 18 years of age) is not recommended because safety and efficacy have not been established.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding due to a lack of sufficient human safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Cardimax (Levocarnitine) is defined by required monitoring protocols and restrictions due to specific pharmacodynamic and exposure-altering effects documented by regulatory bodies.


Pharmacodynamic and Exposure Interactions

Interacting Substance/Category Mechanism Basis Required Action/Constraint
Coumarinic Anticoagulants (e.g., Warfarin, Acenocoumarol) Increased Anticoagulation Effect leading to an increase in the International Normalised Ratio (INR). Mandatory INR Monitoring: INR levels must be checked weekly until stable, and monthly thereafter, following initiation or dose adjustment.
Hypoglycaemic Agents (e.g., Insulin, Oral Treatments) Risk of Hypoglycaemia due to an additive effect on glucose metabolism. Mandatory Glucose Monitoring: Plasma glucose levels must be monitored regularly to permit immediate adjustment of the antidiabetic therapy.

Exposure and Substance Notes

  • Anticonvulsants The use of certain anticonvulsant medicines, including Valproic Acid, Carbamazepine, and Phenytoin, is officially associated with a decrease in plasma levocarnitine concentrations.
  • Sorbitol-containing Products The oral solution formulation of Cardimax contains the excipient sorbitol. Regulatory information states that the additive effect of concurrently administered products or dietary intake containing sorbitol must be taken into account.

Regulatory Structure

The official documentation defines the product's interaction structure around specific procedural constraints. This requires rigorous surveillance of INR in patients on anticoagulants and glucose levels in diabetic patients to manage the officially documented pharmacodynamic and exposure-altering risks.

Mechanism of Action

Targeting the Mitochondrial Fuel Carrier System

Cardimax (Levocarnitine) acts as an essential carrier molecule, engaging the enzymes Carnitine Palmitoyltransferase I ( CPT-I) and II ( CPT-II) and the transporter Carnitine Acylcarnitine Translocase ( CACT), which are positioned at the mitochondrial membrane. This interaction facilitates the crucial step of transporting long-chain fatty acids into the cell's powerhouse for metabolism . This mechanism ensures that energy substrate delivery is maintained, contributing to cellular metabolic integrity.


️ Restoring Cellular Energy and Acyl Group Detoxification

By restoring the mitochondrial transport system, Levocarnitine directly enables the Fatty Acid beta-Oxidation pathway, resulting in the generation of Adenosine Triphosphate (ATP) for organs like the heart and muscle. Furthermore, this action prevents the accumulation of potentially toxic acyl-CoA esters, a physiological consequence that facilitates the maintenance of cellular and membrane structure.

Dosage and Administration Information

How to Use Cardimax — Administration Guidelines

Cardimax is a brand name associated with different active ingredients (Diltiazem or Trimetazidine) across various markets. The instructions for use vary significantly based on the specific formulation and active ingredient as defined in regulatory labeling.


Administration Routes and Forms

Administration Route Applicable Forms
Oral Immediate-Release (IR) Tablets, Extended-Release (ER) Capsules/Tablets (Diltiazem/Trimetazidine)
Intravenous (IV) Solution for Injection (Diltiazem Hydrochloride)

Standard Dosing and Frequency

Oral administration is structured based on the release mechanism. Immediate-Release Diltiazem is typically taken four times daily (QID). Extended-Release Diltiazem forms are generally taken once daily (QD), while Trimetazidine Modified-Release is usually taken twice daily (BID), most often during meals. The standard doses are defined in labeling and may be titrated by a healthcare provider at prescribed intervals, such as every 7 to 14 days for Diltiazem.


Preparation and Special Conditions

Oral forms must generally be swallowed whole. Extended-Release products, in particular, must not be crushed, chewed, or divided. However, certain Diltiazem ER capsules permit sprinkling the contents onto soft food (e.g., applesauce) if swallowed immediately without chewing. Trimetazidine modified-release tablets must be administered with meals.

For Intravenous Diltiazem, the drug must be diluted prior to continuous infusion using approved diluents, and the bolus is administered over a specific time (e.g., 2 minutes).


Population-Specific Rules

Dosage adjustments are mandated for certain patient populations. For example, the dose of Trimetazidine must be reduced in patients with moderate renal impairment (e.g., to 35 mg once daily). Use in patients under 18 years old is generally not recommended for Trimetazidine as safety and efficacy have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus

Studies have been conducted to investigate the compound’s activity regarding key pro-inflammatory cytokines, specifically IL-6 and TNF-alpha. Further research has explored the possibility of binding to specific receptor sites and its relationship to managing chronic inflammatory conditions.


Efficacy Data: Core Findings

Clinical trials evaluated whether the compound could affect joint function and pain over a period of time.

A single Randomized Controlled Trial (RCT) involving 450 participants reported measured differences in measures of physical function compared to placebo. Data indicated that results were observed in the group receiving the active compound, with the earliest assessment point at 4 weeks. These studies were generally focused on individuals with moderate-to-severe disease activity.

Smaller, non-blinded studies explored whether the compound might affect inflammation and swelling, and examined outcomes in participants who also received physical therapy. Findings from these limited studies were mixed.


Long-Term Research and Combination Use

Phase III trials were conducted to investigate the potential relationship between the compound and disease progression.

The available evidence remains limited, and the compound has not been studied as a substitute for standard care. Long-term (greater than 2 years) data is not yet available to confirm the durability of the observed findings.

Studies involving combination therapy evaluated patient outcomes when the compound was administered along with a standard disease-modifying antirheumatic drug (DMARD). Research indicated measured differences in outcome measures when the compound was administered alongside a standard DMARD versus DMARD monotherapy. However, the overall sample size remains small.

Key Studies & References

  1. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial

Frequently Asked Questions (FAQ)

Common questions about Cardimax (FAQ)

Q: Is Cardimax used to prevent heart attacks?

A: Regulatory information indicates that one active ingredient associated with Cardimax in certain markets, Diltiazem, is prescribed for conditions like hypertension. For the Diltiazem-containing formulation, its use in lowering blood pressure is known to be part of an overall strategy for reducing cardiovascular risk. The active ingredient Levocarnitine primarily functions to support energy metabolism in the heart.

Q: What foods or drinks should be avoided while on Cardimax?

A: If you are taking the oral liquid form of Cardimax (Levocarnitine), official product information states you should consider the total amount of sorbitol-containing products or dietary fructose you consume. This is necessary because the medication itself contains sorbitol. The official labeling does not specify general food or drink restrictions outside of the sorbitol/fructose guidance.

Q: What is the difference between Cardimax and Aspirin?

A: Cardimax (Levocarnitine) is classified as a metabolic agent, meaning its function is to facilitate fat metabolism and correct energy deficiencies within the body. In contrast, Aspirin is classified as a non-steroidal anti-inflammatory drug (NSAID) and a platelet inhibitor, used to reduce pain, fever, inflammation, or blood clotting.

Q: Can Cardimax cause dizziness or lightheadedness?

A: Official adverse reaction reports for the active ingredient, Levocarnitine, list dizziness as one of the reported side effects. Dizziness is a reported side effect, and any persistent or bothersome symptoms should be discussed with a healthcare provider.

Q: Why do some people with heart conditions take Cardimax long-term?

A: The active ingredient, Levocarnitine, functions to help transport fatty acids into the cell's mitochondria, where they are used to generate Adenosine Triphosphate (ATP). The intended mechanism is to facilitate the transport of fatty acids to generate ATP for the heart, which is why it is used as a metabolic support agent in specific conditions.

Q: Is the research on Cardimax recent or based on older studies?

A: Clinical trials, including Phase III studies, have been conducted to evaluate the product’s use. Official information indicates that long-term data (over two years) regarding the durability and safety of the compound is still limited or not yet fully available, suggesting research is ongoing.

Q: Can elderly patients safely take Cardimax?

A: Official guidance on the use of Trimetazidine (an active ingredient associated with the product in some markets) requires caution in patients over 75 years old, primarily due to potential age-related changes in kidney function. The Levocarnitine label does not list advanced age as a specific contraindication.

Q: Can women who are planning to get pregnant take Cardimax?

A: If the medicine contains Trimetazidine, its use is not recommended during pregnancy due to insufficient human safety data. Official advice states that a healthcare provider should be informed if a patient is pregnant or trying to become pregnant.

Q: What should I tell my dentist before a procedure if I'm taking Cardimax?

A: Official interaction data for Levocarnitine notes an increased International Normalised Ratio (INR) in patients simultaneously taking certain blood thinners, which is relevant to the risk of bleeding. Due to the possibility of an increased INR when taken with certain blood thinners, patients are advised to share their medication list with their dentist before procedures.

Q: Does Cardimax help with chest pain or angina?

A: Active ingredients like Trimetazidine and Diltiazem, which are associated with Cardimax in some international markets, are indicated for the symptomatic treatment of stable angina pectoris (chronic chest pain). This usage is defined by official regulatory documents for those specific formulations.

Q: What are the most common side effects people report when taking Cardimax?

A: According to official reports, the most frequently observed adverse effects for Levocarnitine involve the digestive system. These include nausea, vomiting, diarrhea, and abdominal cramps. Some people may also notice a characteristic body odor (described as 'fishy').

Q: Will Cardimax interact with my daily multivitamin?

A: While specific interactions between Cardimax and a multivitamin are not usually detailed in official regulatory documents, the patient label generally advises providing your healthcare provider with a complete list of all medicines, herbs, non-prescription drugs, or dietary supplements you are using for a comprehensive safety review.

Q: Can taking Cardimax make me feel tired or fatigued?

A: Official safety information for the oral form of Levocarnitine does not list fatigue as a common adverse reaction. However, a general feeling of tiredness or weakness is sometimes noted as a side effect, particularly with the injectable form of the drug.

Q: How long does the effect of one dose of Cardimax usually last?

A: The duration of a dose's effect is related to the drug's half-life—the time it takes for half of the substance to be eliminated from the body. For Trimetazidine, an active ingredient in some Cardimax products, the biological half-life is approximately 7.81 hours in healthy individuals.

Q: Is it normal to have mild headaches when starting Cardimax?

A: Yes, regulatory documentation lists headache as one of the more common adverse reactions reported by patients taking the active ingredient Levocarnitine. Headache is listed as a common reaction; any severe or worsening symptoms warrant discussion with a healthcare provider.

Q: Can Cardimax be taken on an empty stomach?

A: Official labeling for the Levocarnitine oral solution recommends that it be consumed during or after meals. Taking the medication with food can help maximize the patient's tolerance and reduce the risk of gastrointestinal side effects.

Q: What are the signs of an allergic reaction to Cardimax?

A: Official safety information indicates the potential for allergic reactions, including serious hypersensitivity. Signs reported include rash, hives, or swelling, particularly in the face or throat (edema). Serious reactions like anaphylaxis require immediate attention.

Q: Does alcohol consumption interfere with how Cardimax works?

A: A specific pharmacological interaction between Levocarnitine and alcohol is not generally detailed in regulatory documents. Patients are generally advised to discuss their alcohol consumption with their healthcare provider to assess overall risk while taking the medication.

Q: Why is consistent timing important when taking Cardimax?

A: For the oral solution, official instructions emphasize that doses should be spaced evenly throughout the day and consumed slowly. This consistent timing helps to maximize drug tolerance and reduce the occurrence of gastrointestinal side effects.

Q: Is it okay to take over-the-counter cold medicine while on Cardimax?

A: Official patient information advises providing a healthcare provider with a list of all non-prescription drugs they are using, including cold medicines. This is because no specific interaction with common cold medicine ingredients is detailed, and a full review is recommended.

Q: Does Cardimax interact with herbal supplements like St. John's Wort?

A: Official regulatory documents advise patients to provide a healthcare provider with a list of all herbs they use. This is standard guidance, although no specific interaction with St. John's Wort or other herbal supplements is explicitly detailed in the Levocarnitine label.

Q: Is it normal for my heart rate to change slightly after taking Cardimax?

A: While clinical studies have investigated the drug's effect on general cardiac functional grading, the official safety label does not cite a specific change in heart rate as an expected or common adverse reaction of Levocarnitine. If any changes in heart rate are noticed, it should be brought to the attention of a healthcare provider.

Q: Can Cardimax affect sleep patterns?

A: The active ingredient L-carnitine is sometimes included in commercial products that claim to support sleep. However, the single-ingredient Levocarnitine regulatory label does not list an effect on sleep patterns as a documented pharmacological effect or common adverse reaction.

Q: Does taking Cardimax affect laboratory blood test results?

A: Official prescribing information recommends that monitoring of blood chemistries and plasma carnitine concentrations be performed during therapy. This confirms that blood tests are used to assess the drug's effectiveness and status within the body.

Q: How long after stopping Cardimax does it stay in the system?

A: The time it takes for a medicine to be effectively cleared from the body is based on its half-life. For Trimetazidine, an active ingredient in some Cardimax products, the biological half-life in healthy subjects is approximately 7.81 hours.

Q: Does Cardimax affect cholesterol levels?

A: Since Levocarnitine is a metabolic agent, its primary role is in lipid metabolism (which involves fats and cholesterol). Studies have been conducted to investigate the effect of Levocarnitine on lipid profiles, but the overall results from this research have been inconsistent.

How should Cardimax be stored and disposed of?

How to Store and Dispose of Cardimax (Levocarnitine)

Cardimax must be stored at Controlled Room Temperature, which is 20^circC to 25^circC (68^circF to 77^circF). Storage excursions between 15^circC and 30^circC are permissible. The injectable solution must not be frozen. All forms should be kept in their original container and stored out of the sight and reach of children.

For the oral solution, the bottle must be kept tightly closed and the unused portion must be discarded two months after the initial opening.

Unused or expired Cardimax must be disposed of according to local requirements. The product should not be disposed of via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardimax found in:

A-Z Index: